Advanced search
Publication Cover
Expert Opinion on Drug Metabolism & Toxicology Volume 13, 2017 - Issue 6
Submit an article Journal homepage
963
Views
20
CrossRef citations to date
0
Altmetric
Articles

Prediction of successful dose reduction or discontinuation of adalimumab, etanercept, or infliximab in rheumatoid arthritis patients using serum drug levels and antidrug antibody measurement

CAM BoumanDepartment of Rheumatology, Sint Maartenskliniek, Nijmegen, The NetherlandsCorrespondence[email protected]
View further author information
,
N van HerwaardenDepartment of Rheumatology, Sint Maartenskliniek, Nijmegen, The NetherlandsView further author information
,
FHJ van den HoogenDepartment of Rheumatology, Sint Maartenskliniek, Nijmegen, The Netherlands;Department of Rheumatology, Radboud University Medical Center, Nijmegen, The NetherlandsView further author information
,
A van der MaasDepartment of Rheumatology, Sint Maartenskliniek, Nijmegen, The NetherlandsView further author information
,
BJF van den BemtDepartment of Pharmacy, Sint Maartenskliniek, Nijmegen, The Netherlands;Department of Pharmacy, Radboud University Medical Center, Nijmegen, The NetherlandsView further author information
&
AA den BroederDepartment of Rheumatology, Sint Maartenskliniek, Nijmegen, The Netherlands;Department of Rheumatology, Radboud University Medical Center, Nijmegen, The NetherlandsView further author information
Pages 597-604 | Received 08 Feb 2017, Accepted 13 Apr 2017, Published online: 24 Apr 2017

Citations (20)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (3)

J Ruwaard, MJ L’ Ami, EL Kneepkens, CLM Krieckaert, MT Nurmohamed, F Hooijberg, AWR van Kuijk, JC van Denderen, L Burgemeister, T Rispens, M Boers & GJ Wolbink. (2023) Interval prolongation of etanercept in rheumatoid arthritis, ankylosing spondylitis, and psoriatic arthritis: a randomized controlled trial. Scandinavian Journal of Rheumatology 52:2, pages 129-136.
Read now
Lise Pedersen, Pal Bela Szecsi, Per Birger Johansen & Poul Jannik Bjerrum. (2020) Evaluation of Therapeutic Drug Monitoring in the Clinical Management of Patients with Rheumatic Diseases: Data from a Retrospective Single-Center Cohort Study. Biologics: Targets and Therapy 14, pages 115-125.
Read now
Noortje Van Herwaarden, Bart J.F. Van Den Bemt, Maike H.M. Wientjes, Cornelis Kramers & Alfons A. Den Broeder. (2017) Clinical utility of therapeutic drug monitoring in biological disease modifying anti-rheumatic drug treatment of rheumatic disorders: a systematic narrative review. Expert Opinion on Drug Metabolism & Toxicology 13:8, pages 843-857.
Read now

Articles from other publishers (17)

Charlotte LM Krieckaert, Astrid van Tubergen, Johanna Elin Gehin, Borja Hernández-Breijo, Guillaume Le Mélédo, Alejandro Balsa, Peter Böhm, Sasa Cucnik, Ori Elkayam, Guro L Goll, Femke Hooijberg, Meghna Jani, Patrick DW Kiely, Neil McCarthy, Denis Mulleman, Victoria Navarro-Compán, Katherine Payne, Martin E Perry, Chamaida Plasencia-Rodriguez, Simon R Stones, Silje Watterdal Syversen, Annick de Vries, Katherine M Ward, Gertjan Wolbink & John D Isaacs. (2023) EULAR points to consider for therapeutic drug monitoring of biopharmaceuticals in inflammatory rheumatic and musculoskeletal diseases. Annals of the Rheumatic Diseases 82:1, pages 65-73.
Crossref
Johanna Elin Gehin, Guro Løvik Goll, Marthe Kirkesæther Brun, Meghna Jani, Nils Bolstad & Silje Watterdal Syversen. (2022) Assessing Immunogenicity of Biologic Drugs in Inflammatory Joint Diseases: Progress Towards Personalized Medicine. BioDrugs 36:6, pages 731-748.
Crossref
Charlotte Krieckaert, Borja Hernández-Breijo, Johanna Elin Gehin, Guillaume le Mélédo, Alejandro Balsa, Meghna Jani, Denis Mulleman, Victoria Navarro-Compan, Gertjan Wolbink, John D Isaacs & Astrid van Tubergen. (2022) Therapeutic drug monitoring of biopharmaceuticals in inflammatory rheumatic and musculoskeletal disease: a systematic literature review informing EULAR points to consider. RMD Open 8:2, pages e002216.
Crossref
Konstantinos Papamichael, Waqqas Afif, David Drobne, Marla C Dubinsky, Marc Ferrante, Peter M Irving, Nikolaos Kamperidis, Taku Kobayashi, Paulo G Kotze, Jo Lambert, Nurulamin M Noor, Xavier Roblin, Giulia Roda, Niels Vande Casteele, Andres J Yarur, Naila Arebi, Silvio Danese, Stephane Paul, William J Sandborn, Séverine Vermeire, Adam S Cheifetz & Laurent Peyrin-Biroulet. (2022) Therapeutic drug monitoring of biologics in inflammatory bowel disease: unmet needs and future perspectives. The Lancet Gastroenterology & Hepatology 7:2, pages 171-185.
Crossref
Johanna Elin Gehin, Silje Watterdal Syversen, David John Warren, Guro Løvik Goll, Joseph Sexton, Nils Bolstad & Hilde Berner Hammer. (2021) Serum etanercept concentrations in relation to disease activity and treatment response assessed by ultrasound, biomarkers and clinical disease activity scores: results from a prospective observational study of patients with rheumatoid arthritis. RMD Open 7:3, pages e001985.
Crossref
Binglong Wang, Yujue He, Jifeng Tang, Qishui Ou & Jinpiao Lin. (2020) Alteration of the gut microbiota in tumor necrosis factor‐α antagonist‐treated collagen‐induced arthritis mice. International Journal of Rheumatic Diseases 23:4, pages 472-479.
Crossref
Martin Perry, Azhar Abdullah, Marina Frleta, Jonathan MacDonald & Andrew McGucken. (2020) The potential value of blood monitoring of biologic drugs used in the treatment of rheumatoid arthritis. Therapeutic Advances in Musculoskeletal Disease 12, pages 1759720X2090485.
Crossref
Jordi Gratacós, Caridad Pontes, Xavier Juanola, Jesús Sanz, Ferran Torres, Cristina Avendaño, Antoni Vallano, Gonzalo Calvo, Eugenio de Miguel & Raimon Sanmartí. (2019) Non-inferiority of dose reduction versus standard dosing of TNF-inhibitors in axial spondyloarthritis. Arthritis Research & Therapy 21:1.
Crossref
Lisa K. Stamp, Suz Jack Chan, Carlo Marra, Caitlin Helme & Gareth J. Treharne. (2019) Tapering biologic therapy for people with rheumatoid arthritis in remission: A review of patient perspectives and associated clinical evidence. Musculoskeletal Care 17:3, pages 161-169.
Crossref
José Miguel Senabre Gallego, Jose Rosas, Mariana Marco-Mingot, José Alberto García-Gómez, Gregorio Santos-Soler, Esteban Salas-Heredia, Ana Pons-Bas, Xavier Barber-Vallés, José Antonio Bernal-Vidal, Catalina Cano-Pérez, Mario García-Carrasco & Emilio Flores-Pardo. (2019) Clinical relevance of monitoring serum adalimumab levels in axial spondyloarthritis. Rheumatology International 39:5, pages 841-849.
Crossref
Femke B G Lamers-Karnebeek, Johannes W G Jacobs, Timothy R D J Radstake, Piet L C M van Riel & Tim L Jansen. (2019) Adalimumab drug and antidrug antibody levels do not predict flare risk after stopping adalimumab in RA patients with low disease activity. Rheumatology 58:3, pages 427-431.
Crossref
Edwin Jáuregui, Wilson Bautista, Adriana Beltrán, Oscar Felipe, Andrés Fernández, Daniel Fernández, Juan José Jaller, Lina Saldarriaga & Carlos Toro. (2019) Colombian Association of Rheumatology. Consensus on recommendations to decrease and discontinue biological therapy in patients with rheumatoid arthritis, ankylosing spondylitis, and psoriatic arthritis. Revista Colombiana de Reumatología (English Edition) 26:1, pages 11-23.
Crossref
Edwin Jáuregui, Wilson Bautista, Adriana Beltrán, Oscar Felipe, Andrés Fernández, Daniel Fernández, Juan José Jaller, Lina Saldarriaga & Carlos Toro. (2019) Asociación Colombiana de Reumatología. Consenso sobre recomendaciones para disminución y descontinuación de la terapia biológica en pacientes con artritis reumatoide, espondilitis anquilosante y artritis psoriásica. Revista Colombiana de Reumatología 26:1, pages 11-23.
Crossref
E. V. Voronina, N. V. Lobanova, I. R. Yakhin, N. A. Romanova & Yu. A. Seregin. (2018) ROLE OF TUMOR NECROSIS FACTOR ALPHA IN IMMUNE PATHOGENESIS OF DIFFERENT DISEASES AND ITS SIGNIFICANCE FOR EVOLVING ANTICYTOKINE THERAPY WITH MONOCLONAL ANTIBODIES. Medical Immunology (Russia) 20:6, pages 797-806.
Crossref
Bruno Fautrel. (2018) Therapeutic strategy for rheumatoid arthritis patients who have achieved remission. Joint Bone Spine 85:6, pages 679-685.
Crossref
Alfons A. den Broeder, Noortje van Herwaarden & Bart J.F. van den Bemt. (2018) Therapeutic drug monitoring of biologicals in rheumatoid arthritis: a disconnect between beliefs and facts. Current Opinion in Rheumatology 30:3, pages 266-275.
Crossref
Bruno Fautrel. (2018) Que faire une fois la rémission obtenue dans la polyarthrite rhumatoïde. Revue du Rhumatisme Monographies 85:1, pages 25-31.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.